| Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (NCT05158140) | Merck Sharp & Dohme LLC | 2022-01-12 |
| Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) (NCT04665050) | Merck Sharp & Dohme LLC | 2021-02-04 |
| The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (NCT03489018) | London School of Hygiene and Tropical Medicine | 2019-03-21 |
| A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults (NCT03549208) | LG Chem | 2018-07-01 |
| Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (NCT03619252) | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 2018-07-01 |
| A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants (NCT03467984) | LG Chem | 2018-05-25 |
| Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan (NCT03341195) | Aga Khan University | 2018-01-01 |
| A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax (NCT02572635) | ImmunoBiology Limited | 2015-10-01 |
| Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis (NCT02463539) | Assistance Publique - Hôpitaux de Paris | 2015-09-01 |
| Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis (NCT02463578) | Assistance Publique - Hôpitaux de Paris | 2015-06-01 |
| Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers (NCT02279589) | Assistance Publique - Hôpitaux de Paris | 2014-12-04 |
| Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) (NCT02260882) | Merck Sharp & Dohme LLC | 2014-10-31 |
| Systems Biology of PNEUMOVAX®23 and PREVNAR 13® (NCT01307449) | Emory University | 2014-04-01 |
| Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults (NCT02062281) | Jiangsu Province Centers for Disease Control and Prevention | 2013-11-01 |
| Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia (NCT03095326) | Fakultas Kedokteran Universitas Indonesia | 2013-09-01 |
| Aerosolized and Intravenous Colistin in Healthy Adults (NCT01863719) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-08-06 |
| Pneumonia Vaccine in Aging HIV Positive Individuals (NCT02558751) | University of Toledo Health Science Campus | 2013-07-01 |
| A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (NCT01654263) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-10-10 |
| A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China (NCT01692886) | Pfizer | 2012-09-01 |
| A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects (NCT01531322) | Pfizer | 2011-10-01 |
| Immune Response to Pneumococcal Vaccination in HIV Infected Individuals (NCT02515240) | University of Toledo Health Science Campus | 2010-07-01 |
| A Retrospective Epidemiological Study on Pneumococcal Infection in Children in Ministry of Health Hospital at EHSA Region in the Eastern Province (NCT00844467) | King Saud University | 2009-02-01 |
| Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (NCT00560950) | Merck Sharp & Dohme LLC | 2007-07-01 |
| ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) (NCT00535730) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) (NCT00496093) | Merck Sharp & Dohme LLC | 2005-10-01 |
| 9-valent CRM 197 Pneumococcal (NCT00133549) | National Institute of Allergy and Infectious Diseases (NIAID) | 2000-11-01 |